Amy Feldman
Forbes senior editor covering healthcare. Email afeldman@forbes.com, signal amyfeldman.33
- In the latest Current Climate newsletter: ☀️ Trump’s green ‘scam’ is the top source of new U.S. electricity 🏢 Aiding the power crunch with more efficient buildings ⚡️Jason Few on using fuel cells to help curb data center pollution #renewableenergy #energyefficiency www.forbes.com/sites/curren...
- In this week's edition of our healthcare newsletter, InnovationRx, @amyfeldman7.bsky.social and I look at the New York city nurses’ strike, why Yann LeCun’s AI startup is focused on healthcare, Epic’s new predictive tools, and more. www.forbes.com/sites/innova...
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- In this week's edition of our healthcare newsletter, InnovationRx, @amyfeldman7.bsky.social and I take a look at Medline's upcoming blockbuster IPO, how Fred Moll is pushing the future of robotic surgery, the inaugural Forbes Top Hospitals list and more! www.forbes.com/sites/innova...
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- In this week's edition of InnovationRx, @amyfeldman7.bsky.social and I look at: 💵 The Senate punting on Obamacare subsidies 🧪 Diagnostics company BillionToOne's IPO 🧬 Lilly's deal with MeiraGTx for a gene therapy to treat a form of blindness And more! www.forbes.com/sites/innova...
- [Not loaded yet]
- Interesting story from @forbes.com @amyfeldman7.bsky.social on IPO of a biotech company doing non-invasive prenatal tests. up next: new diagnostic products including those that could be used in early detection of cancer, one of the holy grails of testing.
- Today’s hot IPO: a medical diagnostics company that hit $5.8B market cap after share soared 80%+ @forbes.com www.forbes.com/sites/amyfel...
- [Not loaded yet]
- New edition of our healthcare newsletter, InnovationRx, is here. In it, @amyfeldman7.bsky.social and I take a look at: 🧠 What to know about President Trump's cognitive test. 💻 New Nvidia collaborations in healthcare. 🤖 How robots can save time and manpower at hospitals And more!
- [Not loaded yet]
- [Not loaded yet]
- OpenEvidence’s CEO and cofounder Daniel Nadler is $1.3 billion richer in just three months after the AI startup hit a $6 Billion valuation. With @amyfeldman7.bsky.social. www.forbes.com/sites/amyfel...
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- AI search tool OpenEvidence is already used by 40% of doctors in the U.S. Now it's raised $210 million from GV and Kleiner Perkins at a $3.5 billion. That investment makes CEO Daniel Nadler a billionaire by Forbes estimates. With @amyfeldman7.bsky.social. www.forbes.com/sites/amyfel...
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- New York friends! I’ll be in Greenwich Village next Tuesday evening for this lovely event — come through and say hi :) www.nyfwa.org/nyfwa-event/...
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
- The latest edition of our healthcare newsletter, InnovationRx, is here. Inside, @amyfeldman7.bsky.social and I look at: 💉 The patent fight over the injectable version of Merck cancer drug Keytruda. 🧪 Highlights from this year's AACR meeting. 👨🔬 A new blood test for multiple myeloma And more!
- [Not loaded yet]
- [Not loaded yet]
- [Not loaded yet]
